To assess the safety profile of Mysimba, its manufacturer, Orexigen, held five placebo-controlled clinical trials. The results of these studies proved that the potential benefit of Mysimba in weight reduction exceeds the risks of any adverse reactions.
Most adverse reactions of Mysimba are dose-depended. For example, increase in Mysimba dose can cause gastrointestinal side effects, such as constipation. The most frequent adverse reactions of Mysimba are anxiety, abdominal pain, arthralgia, and myalgia.
- Nausea, cramps, vomiting, headache and dizziness were the leading side effects that led to the cessation of Mysimba use.
- In most subjects, these side reactions of Mysimba were manageable and had a mild transient nature.
- Interaction of Mysimba with antidiabetic drugs, such as Metformin (aka Glucophage), increases the risk of gastrointestinal adverse reactions, like gastroparesis or diarrhea. In this regard, obese diabetics may need to reduce the dose of Mysimba.
- In geriatric patients on Mysimba, the risk of adverse events is higher than in young obese patients. Therefore, older people with excess weight may require titration of the daily Mysimba dose.
The list of very rare adverse reactions of Mysimba includes:
- Dry mouth
- Blurred vision
- Libido disorder.
Rarely, Mysimba can cause neurological adverse reactions, including nervousness, tremors, abnormal dreams, depression, drowsiness, or fatigue.
Active Ingredients of Mysimba
Mysimba can also cause insomnia, due to which these diet pills are not recommended to be taken in the evening or before going to sleep.
Bupropion, one of the active ingredients of Mysimba, can cause hypertension.
However, the results of clinical studies prove that Mysimba does not cause significant changes in blood pressure, when used for less than one year. In general, the adverse reactions of Mysimba are of a short, moderate or mild nature. They may appear in about a month after the beginning of Mysimba use, and disappear completely during the course of the pharmacotherapy of obesity.